A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension: Results of a non-investigational study in the Czech Republic

Main Article Content

Ulrike Hostalek J. Bruthans E. M.W. Koch

Abstract

Summary


Objective:


This non-investigational study with the primary goal to assess patient adherence to the fixed dose combination (FDC) of bisoprolol and amlodipine in daily practice was carried out in six countries in Eastern Europe, in Czech Republic, Hungary, Poland, Romania, Serbia and Slovakia. In this paper, the results of 740 patients recruited in Czech Republic are presented. Secondary objectives included the assessment of blood pressure, pulse pressure values and heart rate.


Material and Methods


Patients eligible for recruitment were over 18 years of age, had essential hypertension, had already been switched from a free combination of bisoprolol 5–10mg/d and amlodipine 5–10mg/d to the FDC at least 4 weeks prior to recruitment, and gave informed consent. Women in childbearing age were under reliable contraception.


Exclusion criteria included pregnancy, lactation, any contraindication to the FDC according to the local label and any other antihypertensive medication.  


The primary target parameter was patient adherence under the FDC. Adherence was measured by tablet count (tablets taken divided by tablets prescribed, times 100). The definition was as follows: excellent >90%, good 76-90%, moderate 51-75%, bad <50%. The study hypothesis was that at least 90% of the patients showed good to excellent adherence.


All other patient data, clinical findings and laboratory values were recorded upon availability at study start and after 6 months.


Results


There were more male (383, 52%) than female (357, 48%) patients. The mean age was 58.8 years with a Q1 – Q3 interval of 51 to 68 years. The youngest patient was 23 years and the oldest 95 years old. All patients had been pretreated once daily with a free combination of bisoprolol (mean 5.8mg) and amlodipine (mean 5.9mg). In most patients, the doses were not changed at the switch to the FDC or later during the study, resulting in a mean of 6.2mg for bisoprolol and 5.9mg for amlodipine.


Over the 6 months of treatment, the adherence of 98% of the patients was good to excellent. Thus, the study expectation was more than met.


Potentially due to the excellent adherence, there was a 12.1mmHg reduction in mean systolic and a 6.9mmHg reduction in mean diastolic blood pressure after 6 months compared to study start. The benefits of patient adherence on blood pressure control are confirmed by the improvement of the pulse pressure by an average of 59.1mmHg±13 at study start versus 54.1mmHg±10 after 6 month of treatment. Heart rate decreased by a mean of 5.6bpm.


Only in 2 patients (0.3%), two adverse drug reactions probably related to the study medication were documented after 6 months: one case of hypotension and one case of edema. None of the adverse drug reactions (ADR) was considered serious and both patients fully recovered. Overall, the FDC of bisoprolol and amlodipine was well tolerated.


The study results clearly show that the high adherence under the FDC of bisoprolol and amlodipine may contribute to better blood pressure control and, thus, to a better risk reduction for cardiovascular events.

Article Details

How to Cite
HOSTALEK, Ulrike; BRUTHANS, J.; KOCH, E. M.W.. A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension: Results of a non-investigational study in the Czech Republic. Medical Research Archives, [S.l.], v. 5, n. 11, nov. 2017. ISSN 2375-1924. Available at: <http://journals.ke-i.org/index.php/mra/article/view/1395>. Date accessed: 15 dec. 2017. doi: https://doi.org/10.18103/mra.v5i11.1395.
Keywords
medical, medicine,research,pharmacology
Section
Research Articles

References

1. Lloyd-Jones D, Adams RJ, Brown TM et al. Executive summary: heart disease and stroke statistics – 2010 update. Circulation 2010;121:948–54
2. Mancia G, Fagard R, Narkiewicz. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens 2013;31(7):1281– 357
3. Gradman AH, Basile JN, Carter BL et al. ASH Position Article. Combination therapy in hypertension. J A Soc Hypertens 2010;4(1):42-50
4. Neutel JM. Low-dose antihypertensive combination therapy: Its rationale and role in cardiovascular risk management. Am J Hypertens 1999;12:73S-9S
5. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-70
6. Nayler WG. The potential for added benefits with β-blockers and calcium antagonists in treating cardiovascular disorders. Drugs 1988;35(Suppl 4):1-8
7. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension. The cycle repeats. Drugs 2002;62:443-62
8. Waeber B, Feihl F, Ruilope LM. Fixed-dose combinations as initial therapy for hypertension. A review of approved agents and a guide to patient selection. Drugs 2009;69:1761-76
9. Sun N, Hong T, Zhang R et al. The Effects of Verapamil SR and Bisoprolol on Reducing the Sympathetic Nervous System's Activity. Hypertens Res 2000;23:537-40
10. Düsing R. Optimizing blood pressure control through the use of fixed combinations. Vasc Health Risk Manag 2010;6:321-5
11. Mehta S, Shah M, Shah A et al. Efficacy and Tolerability of A Fixed Dose Combination of Amlodipine and Bisoprolol in Essential Hypertension. The Indian Practitioner 2005;58(12):751–9
12. Rana R, Patil A. Efficacy and Safety of Bisoprolol plus Amlodipine Fixed Dose Combination in Essential Hypertension. The Indian Practitioner 2008;61(4):225–34
13. Shirure PA, Tadvi NA Bajait CS et al. Comparative effect 0f fixed dose combination of Amlodipine + Bisoprolol versus Amlodipine and Bisoprolol alone on blood pressure in stage-2 essential hypertensive patients. Int J Med Res Health Sci 2012;1(1):13–9
14. Hostalek U, Li L, Montenego P. Bisoprolol/amlodipine combination therapy improves blood pressure control in patients with essential hypertension following monotherapy failure. CMRO 2016; DOI:10.1080/03007995.2016.1205573
15. Hostalek U, Czarnecka D, Koch EMW. Treatment of Hypertensive Patients with a Fixed-Dose Combination of Bisoprolol and Amlodipine: Results of a Cohort study with More Than 10,000 Patients. Cardiol Ther 2015a DOI 10.1007/s40119-015-0045-z
16. Hostalek U, Czarnecka D, Kurzeja A et al. Efficacy of and Adherence to a Fixed-dose Combination of Bisoprolol and Amlodipine in Hypertensive Patients with and without Type 2 Diabetes Mellitus or Coronary Artery Disease. J Heart Health 2015b; open access
17. Dezii CM. A Retrospective Study of Persistence With Single-Pill Combination Therapy Vs. Concurrent Two-Pill Therapy in Patients With Hypertension. Manag Care 2000;9(9 Suppl):2–6

Most read articles by the same author(s)

Obs.: This plugin requires at least one statistics/report plugin to be enabled. If your statistics plugins provide more than one metric then please also select a main metric on the admin's site settings page and/or on the journal manager's settings pages.